SHIB Surges 5% After Mid-Day Dip, Defying Economic Tensions
After experiencing a significant mid-day sell-off, SHIB staged an impressive recovery during the 22:00 hour, surging 3.0% on nearly 900 billion in volume before establishing a new resistance level at $0.0000147.
Technical Analysis Highlights
HIB established a trading range of 0.000007 (5.24%) between the low of 0.0000139 and high of 0.0000147 over the 24-hour period.
The token experienced a significant sell-off during the 15:00 hour, dropping to its lowest point before finding strong volume support.
A decisive recovery occurred during the 22:00 hour where price surged 3.0% on nearly 900 billion in volume.
Bullish momentum continued into the final hours, with SHIB establishing a new resistance level at 0.0000147.
In the last hour, SHIB experienced notable volatility with a 4.5% price swing between the low of 0.00001453 and high of 0.00001463.
After establishing support at 0.00001455, SHIB staged a strong recovery beginning at 01:26, surging to 0.00001463 by 01:46 on increasing volume that peaked at 30.15 billion.
Momentum faltered in the final 15 minutes as selling pressure emerged, creating a descending channel that brought prices back to 0.00001457.
External References
"Shiba Inu (SHIB) Bucks Market Slump With Unexpected Show Of Price Strength", Coin Edition, published May 23, 2025.
"Shiba Inu Price Hints at $0.000020 Next as New Cryptocurrency Mutuum Finance Goes Viral With 12380% Price Prediction", Cryptopolitan, published May 26, 2025.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
ADCs Set for Growth Amid Regulatory Evolutions and Technological Advances
The Antibody Drug Conjugates Market presents opportunities in developing novel ADC platforms, expanding into new cancer types, and leveraging biomarker-driven patient selection. Growth is driven by increasing demand for targeted therapies, technological advancements, and investment in R&D despite competition and regulatory challenges. Antibody Drug Conjugates Market Dublin, Aug. 15, 2025 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates: Market Share, and Growth Analysis by Product Type (Monoclonal Antibodies, Small Molecule Drugs), Application, End User, Technology" report has been added to Antibody Drug Conjugates Market size is valued at USD 11.1 billion in 2025 and is projected to reach USD 42.2 billion by 2033, registering a compound annual growth rate (CAGR) of 18.2% over the forecast period. The Antibody Drug Conjugates (ADCs) Market focuses on the development and commercialization of targeted cancer therapies. ADCs combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs, delivering the drug directly to cancer cells while minimizing damage to healthy tissues. The market is driven by the increasing demand for targeted cancer therapies with improved efficacy and safety profiles. The market encompasses various ADC platforms, including linkers, payloads, and conjugation market is segmented based on target antigen, payload, linker, and application. The major target antigens include HER2, CD30, and CD33. The market caters to a diverse range of cancer types, including breast cancer, lymphoma, and leukemia. The market is characterized by intense competition among pharmaceutical and biotechnology companies, with a focus on developing novel ADC platforms and expanding the therapeutic applications of Antibody Drug Conjugates Market is subject to stringent regulatory requirements and evolving guidelines regarding cancer therapies. The market is also influenced by the increasing complexity of cancer biology and the need for highly specific and potent ADCs. The market is expected to continue its growth trajectory, driven by the increasing demand for targeted cancer therapies and the development of innovative ADC Insights: Antibody Drug Conjugates Market Development of novel ADC platforms with improved stability and efficacy. Expansion of ADC applications to solid tumors and other cancer types. Increasing use of biomarker-driven patient selection for ADC therapy. Growing interest in combination therapies involving ADCs and other cancer treatments. Rising adoption of next-generation sequencing and other technologies to optimize ADC development. Increasing prevalence of cancer and the need for effective treatments. Growing demand for targeted cancer therapies with improved safety profiles. Technological advancements in ADC development and conjugation technologies. Rising investment in research and development by pharmaceutical and biotechnology companies. Increasing availability of funding and partnerships for ADC development projects. High cost of ADC development and manufacturing. Complexity of ADC design and optimization. Challenges in delivering the payload to cancer cells and minimizing off-target effects. Evolving regulatory requirements and intellectual property considerations. Competition from alternative cancer therapies, such as immunotherapy and cell therapy What's Included in the Report? Global Antibody Drug Conjugates market size and growth projections, 2024-2034 North America Antibody Drug Conjugates market size and growth forecasts, 2024-2034 (United States, Canada, Mexico) Europe market size and growth forecasts, 2024-2034 (Germany, France, United Kingdom, Italy, Spain) Asia-Pacific Antibody Drug Conjugates market size and growth forecasts, 2024-2034 (China, India, Japan, South Korea, Australia) Middle East Africa Antibody Drug Conjugates market size and growth estimate, 2024-2034 (Middle East, Africa) South and Central America Antibody Drug Conjugates market size and growth outlook, 2024-2034 (Brazil, Argentina, Chile) Antibody Drug Conjugates market size, share and CAGR of key products, applications, and other verticals, 2024-2034 Short- and long-term Antibody Drug Conjugates market trends, drivers, challenges, and opportunities Antibody Drug Conjugates market insights, Porter's Five Forces analysis Profiles of 5 leading companies in the industry - overview, key strategies, financials, product portfolio and SWOT analysis Latest market news and developments Key Attributes: Report Attribute Details No. of Pages 150 Forecast Period 2025 - 2033 Estimated Market Value (USD) in 2025 $11.1 Billion Forecasted Market Value (USD) by 2033 $42.2 Billion Compound Annual Growth Rate 18.2% Regions Covered Global Antibody Drug Conjugates Market Segmentation By Product Type: Monoclonal Antibodies Small Molecule Drugs By Application: Oncology Autoimmune Diseases Infectious Diseases By End User: Hospitals Specialty Clinics Research Institutes By Technology: Chemical Linkers Bioconjugation Techniques By Distribution Channel: Direct Sales Distributors By Geography: North America (USA, Canada, Mexico) Europe (Germany, UK, France, Spain, Italy, Rest of Europe) Asia-Pacific (China, India, Japan, Australia, Vietnam, Rest of APAC) The Middle East and Africa (Middle East, Africa) South and Central America (Brazil, Argentina, Rest of SCA) For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Antibody Drug Conjugates Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
an hour ago
- Bloomberg
UnitedHealth Surges After Buffett, Tepper Bet on Turnaround
UnitedHealth Group Inc. shares jumped after funds piled into the company, which has been hampered by a federal probe into its business practices and weakening results. The investments were a welcome reprieve for a company that had seen its stock fall 46% this year. In premarket trading on Friday, the shares rose 10%, which would be the biggest increase since 2020.
Forbes
an hour ago
- Forbes
Forbes Daily: Bitcoin Gets A Reality Check After Recent Surge
Bitcoin's rally to an all-time high Thursday was short lived, as disappointing economic data and limited government interest threw cold water on the white-hot cryptocurrency. The price of bitcoin reached a record of $124,436 early in the day following a 2.6% gain Wednesday, but by late afternoon it was down more than 4%. The Trump Administration has fueled optimism for the crypto market, as the president has indicated he would reduce regulation and establish a digital asset stockpile similar to the U.S. gold reserves. Nonetheless, the U.S. does not plan to buy more crypto for its bitcoin reserve, which holds between $15 billion and $20 billion in assets, Treasury Secretary Scott Bessent said Thursday. Intel had a years-long downturn as it failed to keep up with its competitors in the AI race. NurPhoto via Getty Images Intel shares skyrocketed shortly before the close of trading Thursday as Bloomberg reported the Trump Administration may take a stake in the chipmaker to help the struggling firm strengthen its domestic manufacturing. Trump recently met with CEO Lip-Bu Tan despite calling for his ouster last week, and the company's stock ended the day with a more than 7% gain, its highest level since March. Earlier this week, Paramount signed a blockbuster seven-year deal for the streaming rights to UFC for a staggering $7.7 billion. Considering how Paramount has struggled with profitability for years, it's reasonable to wonder how the newly merged company plans to recoup that value. But new owner and CEO David Ellison—son of world's second richest person, Oracle founder Larry Ellison—has made it clear his intention is to reverse that losing trend. And with the addition of UFC, suddenly Paramount is a real player in the sports media landscape and streaming wars. This is a published version of the Forbes Daily newsletter, you can sign-up to get Forbes Daily in your inbox here. In a shift from Tuesday's positive inflation news, wholesale prices increased more than expected in July, according to the Bureau of Labor Statistics. The price of services drove an increase of 0.9% when only 0.2% had been anticipated, and stocks ended the day mostly flat after initially slipping on the news. WEALTH + ENTREPRENEURSHIP Nike co-founder Phil Knight Getty Images Nike cofounder Phil Knight became the latest billionaire to give a record-setting amount to an educational institution, as he and his wife Penny gifted $2 billion to the Oregon Health & Science University's Knight Cancer Institute. The largest-ever university donation will roughly double the cancer center's size, according to the Wall Street Journal , and allow the institute to 'transform the way we care for patients while continuing to develop innovative treatments,' says its former CEO Dr. Brian Druker. SPORTS + ENTERTAINMENT As 12-time NBA all-star Chris Paul plans for his final season, he's following in the footsteps of basketball stars like Michael Jordan and Magic Johnson by launching a new business venture, The Chris Paul Collective. The entity will house all of his businesses and investments, including his minor equity stake in the most valuable franchise in the NWSL, Angel City FC, which Forbes values at $280 million. TRENDS + EXPLAINERS Members of the National Guard outside Union Station in Washington, DC. Getty Images President Donald Trump has indicated he would replicate his controversial decision to deploy the National Guard and take control of city police in Washington D.C. in other Democrat-led cities, but in reality, he would face far more legal limitations. The president does not have power to influence local police forces in other cities, though Trump would potentially be able to deploy the military through invoking the Insurrection Act. And a lawsuit over Trump's use of the National Guard in Los Angeles could determine how much power local and state officials have to challenge his moves. As the Trump administration moves to reduce federal regulations, states run by Democrats are rushing to fill the gap. The latest example came earlier this week, when New York Attorney General Letitia James announced a lawsuit against the company behind popular money transfer app Zelle, alleging it let fraud proliferate on Zelle for several years and didn't do enough to stop it, costing consumers 'hundreds of millions of dollars.' DAILY COVER STORY Meet The Mastermind Behind The $1.9 Billion Poppi Deal Rohan Oza played a key role in the Poppi deal Ryan West for Forbes Shark Tank veteran Rohan Oza has been searching for the perfect soft drink for the past 20 years. Oza, cofounder of Los Angeles-based private equity firm Cavu Consumer Partners, was the chairman of prebiotic soda Poppi and its single largest individual shareholder when Pepsi acquired it in May for $1.9 billion. It's Oza's biggest exit yet, but it's far from his first, having played a key role in some of the largest beverage acquisitions of the past two decades, including Vitaminwater and Smartwater. On a 2018 episode of ABC's Shark Tank , Oza took a 25% stake in the Austin, Texas-based beverage brand founded by husband-and-wife entrepreneurs Stephen and Allison Ellsworth for $400,000. Then Oza changed everything. He rebranded Mother Beverage, as the Ellsworths had named it, as Poppi. The liquid went from an apple cider vinegar drink to a prebiotic soda, and the packaging changed from glass to cans. The branding morphed from farmer's-market artisanal to bright, Millennial-friendly colors. Leading up to Pepsi's acquisition at a 3.3-times-revenue multiple, Forbes estimates that Oza owned about 21% of Poppi and Cavu owned another 37%. That netted him some $250 million (post-tax) directly from the sale and another roughly $50 million through Cavu. Those proceeds—in addition to exits reinvested and his 50% stake in Cavu—add up to an estimated net worth of roughly $500 million. Such success, says Oza, an immigrant from Zambia who came to the U.S. in 1995, represents his own American Dream. 'There's no consumer audience in the world that is willing to embrace new brands as rapidly as Americans are,' Oza says. 'I came here with a dream. It's full circle.' WHY IT MATTERS 'The quest for the next hit drink is a tale as old as time, and when it comes to modernizing soda today as demand for healthier options soars, Rohan Oza is the one to watch,' says Forbes staff writer Chloe Sorvino. MORE How Surfside Became The Fastest-Growing Alcohol Brand In America FACTS + COMMENTS Taylor Swift announced details about her upcoming album The Life of a Showgirl on Wednesday, drawing over a million viewers to the New Heights podcast on YouTube where the billionaire pop star discussed the record. The show is co-hosted by her boyfriend, Kansas City Chiefs tight end Travis Kelce, and his brother, former Philadelphia Eagles center Jason Kelce: 1.2 million: The number of concurrent viewers the podcast garnered 12: The number of songs on the album, including a title track featuring fellow pop star Sabrina Carpenter Over 6 million: How many copies sold of Swift's last album, The Tortured Poets Department , one of her most commercially successful records STRATEGY + SUCCESS Using AI tools like ChatGPT at work can be a great way to boost productivity, but it also comes with risks that are critical for employees to understand. Start by looking into your company's AI policy, and if one doesn't exist, ask for guidance. Be sure to double-check any AI-generated work and add your personal voice or insights so you don't sound too generic. And never enter your company's proprietary information into public AI tools. VIDEO QUIZ The IRS rolled out technology designed to help taxpayers at its Taxpayer Assistance Centers back in 2011, but a recent audit found only 55% were operational. What kind of technology was it? A. An AI tax chatbot B. A self-service kiosk C. iPads with frequently asked questions D. Robots to issue taxpayer ID numbers Check your answer. Thanks for reading! This edition of Forbes Daily was edited by Sarah Whitmire and Chris Dobstaff.
